(Q35060620)

6 August 2017

1 reference

title

In vitro tests for predicting drug-drug interactions: the need for validated procedures (English)

1 reference

6 August 2017

0 references

Pierre Kremers

1

1 reference

6 August 2017

publication date

1 November 2002

1 reference

Basic and Clinical Pharmacology and Toxicology

6 August 2017

published in

1 reference

6 August 2017

volume

91

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

209-217

1 reference

Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Application of in silico approaches to predicting drug--drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Role of drug metabolism in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Drug glucuronidation in clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Genotoxicity of 1,3- and 1,6-dinitropyrene: induction of micronuclei in a panel of mammalian test cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Experimental and computational screening models for the prediction of intestinal drug absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

In vitro approaches to predicting drug interactions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Assessment of drug-drug interactions: concepts and approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Development of predictive pharmacokinetic simulation models for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

Bioanalytical method validation--a revisit with a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Can drug-drug interactions be predicted from in vitro studies?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Clinical-pharmacological strategies to assess drug interaction potential during drug development

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Sense and nonsense in the prediction of drug-drug interactions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Enzyme kinetics of cytochrome P450-mediated reactions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2002.910501.X

7 January 2021

10.1034/J.1600-0773.2002.910501.X

Identifiers

DOI

1 reference

6 August 2017

1 reference